Since the inaugural congress in 2001, this meeting has become the premier forum for discussion of the latest advances in the field of MyeloProliferative Neoplasms (MPNs) . This year, we will focus on timely topics of interest to hematologists and oncologists who treat patients with these rare disorders. The congress program format will utilize case presentations to highlight the essential features of MPN pathophysiology, diagnosis and management, as well as the roles of next-generation sequencing and the MPN driver mutation and allele burden in clinical decision making.

In addition to defining the role of pegylated interferon and its long-acting derivatives in MPN therapy, the role of immunotherapy in MPNs and novel agents for MPN treatment will be reviewed. New this year will be a discussion of the management of accelerated and blast-phase MPNs, patient selection for bone marrow transplantation, and how to integrate MPN patient symptom scores with therapeutic planning. Congress attendees will have the opportunity to participate in a variety of educational formats including didactic sessions, case reviews, poster sessions and oral abstract presentations, as well as multiple networking and one-on-one discussion opportunities. To allow more time for participant questions, time has also been allotted for a panel discussion with congress faculty.